Last reviewed · How we verify
Teneligliptin and Empagliflozin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Teneligliptin and Empagliflozin (Teneligliptin and Empagliflozin) — Handok Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Teneligliptin and Empagliflozin TARGET | Teneligliptin and Empagliflozin | Handok Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Teneligliptin and Empagliflozin CI watch — RSS
- Teneligliptin and Empagliflozin CI watch — Atom
- Teneligliptin and Empagliflozin CI watch — JSON
- Teneligliptin and Empagliflozin alone — RSS
Cite this brief
Drug Landscape (2026). Teneligliptin and Empagliflozin — Competitive Intelligence Brief. https://druglandscape.com/ci/teneligliptin-and-empagliflozin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab